Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: risedronate

Women on Osteoporosis Drugs Still Need Bone Density Screenings

Lisa Rapaport  |  July 18, 2016

(Reuters Health)—Women with osteoporosis who take bisphosphonates to help avoid fractures still need to have their bone density monitored, a Canadian study suggests. Researchers who studied more than 6,600 women taking osteoporosis drugs found that for nearly one in five, bone mineral density at the hip actually decreased after the women started taking the medication….

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesbone mineral density (BMD)Osteoporosisosteoporosis treatmentsWomen

GI Side Effects Leading Reason for Bisphosphonate Nonadherence

Reuters Staff  |  July 6, 2016

NEW YORK (Reuters Health)—Gastrointestinal side effects are the most common reason osteoporotic women cite for nonadherence to oral bisphosphonate therapy, according to a new survey. “Our findings highlight the importance of low tolerability to nonadherence with osteoporosis therapy and underlines patients’ poor awareness and suboptimal physicians’ involvement in conveying the importance of this therapy,” Dr….

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:adherencebisphosphonatesgastrointestinalOsteoporosisside effectWomen

2015 ACR/ARHP Annual Meeting: Research Lends Insight Into Osteoporosis Treatment, New Auto-Inflammatory Disease, Scleroderma

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—Post-menopausal women with osteoporosis, previously treated with oral bisphosphonates, had greater increases in bone density when taking denosumab compared with zoledronic acid over a year’s time, according to a study presented at the 2015 ACR/ARHP Annual Meeting. The findings were discussed in the Discovery 2015 plenary session, which focused on new research. In the…

Filed under:ConditionsMeeting ReportsOsteoarthritis and Bone DisordersOther Rheumatic ConditionsResearch RheumSystemic Sclerosis Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)auto-inflammatory diseasebisphosphonatesImmunologyOsteoporosisResearchSclerodermaTreatment

Biosimilar Drugs for RA Studied in Multiple Trials

Michele B. Kaufman, PharmD, BCGP  |  August 17, 2015

Etanercept Biosimilars A number of Phase 3 trials are ongoing for etanercept biosimilars.1 One evaluation identified three trials in rheumatoid arthritis (RA) patients and one in psoriasis patients. The psoriatic arthritis trial evaluated PASI as a primary endpoint and the following secondary endpoints: PASI50, PASI75, PASI90, PASI score, laboratory values, ECG, adverse events (AEs), injection…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsoutcomeRheumatoid arthritisrheumatologySafety

Did Reports of Side Effects Contribute to Drop in Bone Drug Use?

Lisa Rapaport  |  July 20, 2015

(Reuters Health)—Media reports raising safety concerns about osteoporosis drugs known as bisphosphonates may have contributed to a sharp drop in their use—even though U.S. doctors and drug regulators haven’t recommended against taking them, a study suggests. Fosamax (alendronate sodium) won U.S. marketing approval in 1995. Widespread use of the drug and others like it over…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:bisphosphonatesFracturesMediaOsteoporosisosteoporosis treatments

The ACR’s State-of-the-Art Clinical Symposium: Rheumatologists Weigh in on Tough-to-Treat Cases, Paget’s Disease, Imaging

Thomas R. Collins  |  July 14, 2015

CHICAGO—A 49-year-old woman has had RA for eight years. She has a rheumatoid factor reading of 35, an aCCP reading of 160, erythrocyte sedimentation rate of 42, plus erosions. She has been on methotrexate. She tried etanercept for six months, but then it stopped working. She was on 40 mg of adalimumab weekly, but it…

Filed under:ConditionsMeeting Reports Tagged with:combination therapydrugimagingoutcomePaget’s diseasepatient careRheumatic Diseaserheumatologisttoxicity

Antirheumatic Drugs May Be Linked to Pulmonary Toxicity & More

Michele B. Kaufman, PharmD, BCGP  |  June 24, 2015

At a recent symposium, Kristin Highland, MD, reported on the use of antirheumatic treatments, specifically methotrexate, and their connections with pulmonary toxicity in patients.

Filed under:Drug Updates Tagged with:ACR 2015 State-of-the-Art Clinical SymposiumDisease-modifying antirheumatic drugs (DMARDs)Methotrexatepulmonary toxicity

FDA Issues Safety Alerts for Bisphosphonates & SGLT2 Inhibitors

Michele B. Kaufman, PharmD, BCGP  |  May 20, 2015

Safety The Food and Drug Administration (FDA) has updated the Warnings and Precautions sections of prescribing information for the bisphosphonate agents, including risedronate sodium tablets and combinations with calcium (Actonel/Atelvia), alendronate and combinations with vitamin D (Binosto/Fosamax), ibandronate (Boniva), etidronate (Didronel) and the RANK-ligand inhibitor denosumab (Prolia/Xgeva).1 This information relates to an increased risk for…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders

Atypical Fractures Associated with Bisphosphonates

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2014

Plus, FX006, odanacatib and other rheumatology drug news, safety updates

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain SyndromesSoft Tissue Pain Tagged with:bisphosphonatesdrugFibromyalgiaFracturesFX006KaufmanodanacatibOsteoporosisosteoporosis treatmentsrheumatologySafety

Drugs Studied for Use in Rheumatoid Arthritis, Weight Loss

Michele B. Kaufman, PharmD, BCGP  |  August 1, 2014

Plus, rheumatology drug news from EULAR 2014

Filed under:Axial SpondyloarthritisConditionsDrug UpdatesEULAR/OtherMeeting ReportsPsoriatic ArthritisRheumatoid Arthritis Tagged with:AC&RAmerican College of Rheumatology (ACR)Ankylosing Spondylitisanti-inflammatorydrugEULARInternationalKaufmanMethotrexatePsoriatic ArthritisRheumatoid arthritisrheumatologistrheumatologySafetytocilizumabweight loss

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences